Improving the dose–myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP
详细信息 查看全文
- 作者：Massimiliano Pacilio (1)
Guido Ventroni (2)
Chiara Basile (1)
Pasquale Ialongo (3)
Domenico Becci (4)
Lucio Mango (2) - 关键词：Red marrow ; Bone metastases ; 153Sm ; EDTMP toxicity ; Radionuclide therapy ; Dosimetry
- 刊名：European Journal of Nuclear Medicine and Molecular Imaging
- 出版年：2014
- 出版时间：February 2014
- 年：2014
- 卷：41
- 期：2
- 页码：238-252
- 全文大小：684 KB
- 作者单位：Massimiliano Pacilio (1)
Guido Ventroni (2)
Chiara Basile (1)
Pasquale Ialongo (3)
Domenico Becci (4)
Lucio Mango (2)
1. Department of Medical Physics, Azienda Ospedaliera San Camillo Forlanini, Piazza Carlo Forlanini no. 1, 00151, Rome, Italy
2. Department of Nuclear Medicine, Azienda Ospedaliera San Camillo Forlanini, Piazza Carlo Forlanini no. 1, 00151, Rome, Italy
3. Department of Radiology, Azienda Ospedaliera San Camillo Forlanini, Piazza Carlo Forlanini no. 1, 00151, Rome, Italy
4. Health Physics Postgraduate School, “Sapienza-University of Rome, Piazzale Aldo Moro no. 5, 00185, Rome, Italy - ISSN：1619-7089
文摘
Purpose 153Sm-ethylene diamine tetramethylene phosphonic acid (153Sm-EDTMP) is widely used to palliate pain from bone metastases, and is being studied for combination therapy beyond palliation. Conceptually, red marrow (RM) dosimetry allows myelotoxicity to be predicted, but the correlation is poor due to dosimetric uncertainty, individual sensitivity and biological effects from previous treatments. According to EANM guidelines, basic dosimetric procedures have been studied to improve the correlation between dosimetry and myelotoxicity in 153Sm-EDTMP therapy. Methods RM dosimetry for 33 treatments of bone metastases from breast, prostate and lung tumours was performed prospectively (with 99mTc-MDP) and retrospectively, acquiring whole-body scans early and late after injection. The 153Sm-EDTMP activity was calculated by prospective dosimetry based on measured skeletal uptake and full physical retention, with the RM absorbed dose not exceeding 3.8?Gy. Patient-specific RM mass was evaluated by scaling in terms of body weight (BW), lean body mass (LBM) and trabecular volume (TV) estimated from CT scans of the L2–L4 vertebrae. Correlations with toxicity were determined in a selected subgroup of 27 patients, in which a better correlation between dosimetry and myelotoxicity was expected. Results Skeletal uptakes of 99mTc and 153Sm (Tc% and Sm%) were well correlated. The median Sm% was higher in prostate cancer (75.3?%) than in lung (60.5?%, p--.005) or breast (60.8?%, p--.008). PLT and WBC nadirs were not correlated with administered activity, but were weakly correlated with uncorrected RM absorbed doses, and the correlation improved after rescaling in terms of BW, LBM and TV. Most patients showed transient toxicity (grade 1-), which completely and spontaneously recovered over a few days. Using TV, RM absorbed dose was in the range 2-?Gy, with a median of 312?cGy for PLT in patients with toxicity and 247?cGy in those with no toxicity (p--.019), and 312?cGy for WBC in those with toxicity and 232?cGy in those with no toxicity (p--.019). ROC curves confirmed the correlations, yielding toxicity absorbed dose thresholds of 265?cGy for PLT and 232?cGy for WBC. Conclusion The best predictor of myelotoxicity and blood cells nadir was obtained scaling the RM absorbed dose in terms of the estimated TV. It seems clear that the increase in skeletal uptake due to the presence of bone metastases and the assumption of full physical retention cause an overestimation of the RM absorbed dose. Nevertheless, an improvement of the dose–toxicity correlation is easily achievable by simple methods, also leading to possible improvement in multifactorial analyses of myelotoxicity.